Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Jan 2024
Oncotarget has published a new research perspective titled "Bone marrow adipocytes provide early sign for progression from mgus to multiple myeloma.".
Read Full NewsSpotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD
Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial
FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis
FDA News Recap: Novel Drug Approvals in Q2 2026
Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.
August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.
Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.
1.
New BCMA-Directed Therapies Show Promise in Multiple Myeloma
2.
FDA Approves Subcutaneous Isatuximab for MM Indications
3.
In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.
4.
Can a Betting Market Offer Hope to a Cancer Patient?
5.
Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation
1.
The Algorithmic Oncologist: A Comparative Clinical Review of AI in Predictive Cancer Planning
2.
A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies
3.
Exploring the Mysteries of Myxoma: A New Frontier in Medical Research
4.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
5.
Geriatric Medicine Through Long-Term Functional Survivorship After Cancer in Older Adults
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
3.
Navigating the Complexities of Ph Negative ALL - Part IX
4.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
5.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge